Mireia Margeli Vila

Distribution of clinical and pathological features in the validation cohort of Hospital Universitario Santa Lucía, Cartagena

Secondary antibodies used for IHC, IF, and WB assays

Integration of three scRNA-seq datasets from adult murine mammary gland

Histological distribution of SMA, TAGL and TPM2 in the validation cohorts of TNBC

Histologic expression of basal markers in breast tumor samples. A, Representative sections of tB- and nB-TNBC samples stained with the indicated BaC markers. Scale bar, 50 μm. B, Bar plots representing the percentage of cells expressing each marker in tB- and nB-TNBCs. *, P < 0.05 based on unpaired t test (Holm–Sidak method); ns, not significant. C, Left, representative images showing TAGL staining in tB- and nB-TNBC tumors. Scale bar, 200 and 50 μm in the insets.

Correlation between ACTA2, TAGLN, and TPM2 expression and drug sensitivity of selected compounds of drug screening

Histologic expression of basal markers in HR-positive breast tumors at different tumor stages. A, Representative sections of HR-positive samples at different tumor stages (LGDCIS, DCIS, and IDC) stained with the indicated basal markers. Scale bar, 50 μm. B, Bar plots representing the percentage of cells expressing each marker in in HR-positive samples across the different tumor stages. Statistics calculated two-way ANOVA. *, P < 0.05; **, P < 0.005; ns, not significant.

Integration of three scRNA-seq datasets from healthy human mammary gland

Evaluation of dasatinib sensitivity in tB-TNBC models in vitro and in vivo. A, Dose–response curves showing cell viability of indicated cell lines treated with increasing concentrations of dasatinib for 72 hours. Solid lines represent the mean of three biological replicates performed in technical replicates normalized to untreated controls, and IC50 values are indicated. B, Representative IHC images of tB-TNBC PDXs (PDX_01 and PDX_02) showing expression of SMA, TAGL, and TPM2. Scale bars, 100 μm. C, Quantification of positive tumor cells for each tB-marker in PDX_01 and PDX_02. Data are shown as mean ± SEM of different tumor areas. D, Schematic representation of the dasatinib treatment protocol. E, Tumor growth curves of the tB-TNBC PDXs treated with vehicle (black) or dasatinib (red). Error bars, ± SEM. P values calculated by Wilcoxon test. F, Bar plot showing tumor weight at the end point. Data are shown as mean ± SEM. P values calculated by two-tailed Student t test. **, P < 0.01. D, Created in BioRender. Rodilla, V. (2026) https://BioRender.com/qpb7bux.

Immunohistochemical validation of basal markers in TNBC samples